Phaseline

Companies › Shanghai SIMR Biotechnology

Shanghai SIMR Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SR1375–Phase 2Community-acquired Pneumonia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06577558SR1375Phase 2Community-acquired PneumoniaRespiratoryOct 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.